All News

colon

GI Abnormalities in Scleroderma

Jack Cush, MD

A prospective Scleroderma Cohort Study found that gastrointestinal tract (GIT) involvement was common and negatively impacted quality of life, physical function, and employment, but had no effect on mortality. 

Read Article
RheumNow Podcast square

Stop Counting Bugs (10.4.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.This week’s rants include the microbiome, PsA treatment choices and fishing for P-values in research.

Read Article
guidelines.jpg (keep)

British Society Guidelines for Managing Behçet’s Disease

Jack Cush, MD

An exhaustive, full read guideline from the British Association of Dermatologists (BAD) and the British Society for Rheumatology (BSR) on the management and treatment of Behçet’s disease (BD) in 2024 has been published in Rheumatology.

Read Article
Methotrexate

Consensus Guidelines on Pediatric Methotrexate Use

Jack Cush, MD

Methotrexate (MTX) is commonly used in the treatment of pediatric inflammatory skin conditions, often for off-label indications. Consensus based recommendations were published to address 5 major subjects.

Read Article
RheumNow Podcast square

Linger on the Fingers (9.6.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week with a focus on fingers and better prescriptive follow through.

Read Article
RheumNow Podcast square

Running with Data (8.30.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com - including tips on steroids, MAS, and myositis testing.

Read Article
RheumNow Podcast square

Depends on Where You’re Looking (8.9.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from RheumNow.com this week.

Read Article
Adult (133,216) vs Pediatric (955) pts on JAKi - analysis of FAERS shows both @ incr risk for infections & GI AEs. Pediatric pts had more blood and lymphatic disorders, while adults had more CNS and MSK/CTD disorders https://t.co/SKjzANYPSq https://t.co/S6JPYuvSlf

Links:

Dr. John Cush RheumNow ( View Tweet)
40 postmenopausal F Rx w/ Blackcurrant (BC) vs PBO. @6 mos BC lowered IL-1β (P .056) & RANKL (P .052) & BMD inversely correlated w/ RANKL change. BC bone protective may also be through enhancing gut microbial balance https://t.co/wy9VR3fwvJ https://t.co/cRCjSb5XDQ

Links:

Dr. John Cush RheumNow ( View Tweet)
Cross-sectional study 69 Systemic Sclerosis Pts: 33% w/ PPI-refractory esophagitis & 2/3 w/ EGD normal esophageal mucosa. PPI-refractory esophagitis was more commonly linked to diffuse SSc subset (43 vs 17%) and GI dysmotility (66 vs 8%; p = <0.001) https://t.co/yIBlyNZacB https://t.co/dempwjX5XO

Links:

Dr. John Cush RheumNow ( View Tweet)
Guselkumab (Tremfy) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, based on pivotal, Phase 2b/3 QUASAR study showing 50% remission at week 44 (vs 19 PBO) for those on GUS 200 mg q 4 wk https://t.co/YgtujQjNqI https://t.co/9uazZLuoRb

Links:

Dr. John Cush RheumNow ( View Tweet)
Systematic literature review IVIG in systemic sclerosis included 12 studies, 266 pts. A favorable effect was seen for skin thickening, MSK pain, GI Sxs, Steroid use, QOL. But less effect for pulmonary Dz, PFTs (stabilized?). Studies were not of high-quality… https://t.co/c3Xix9K2XK https://t.co/L3LKwegmkf
Dr. John Cush RheumNow ( View Tweet)
Cross-sectional study 69 Systemic Sclerosis Pts: 33% w/ PPI-refractory esophagitis & 2/3 w/ EGD normal esophageal mucosa. PPI-refractory esophagitis was more commonly linked to diffuse SSc subset (43 vs 17%) and GI dysmotility (66 vs 8%; p = <0.001) https://t.co/givt90C0tE https://t.co/3oN5qUHpUU

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 4821 pts (age 52 yrs) undergoig EGD - H. pylori infx seen in 2262, w/ long-lasting H Pylori (LLHp) infx in 1043 (21.6%). 6.3% dx w/ aCVD & 4.3% w/ RA. LLHp infection incr risk of aCVS (HR 1.57) & RA (HR 2.63) In RA, LLHp up risk for aCVD (7.89) https://t.co/FNOsEHKVIf https://t.co/dSeJuuuUMQ

Links:

Dr. John Cush RheumNow ( View Tweet)
Is it possible that Helicobacter pylori (Gm neg) can exacerbate or cause RA? Infx of gastric epithelial cell line w/ H. pylori upregulated the expression of PAD4 and increased PAD4 activity, leading to Helicobacter pylori-induced citrullination? https://t.co/QeE3SmWLLp https://t.co/ZG2tYmdJNx

Links:

Dr. John Cush RheumNow ( View Tweet)
Cohort study shows GERD in 1539/1632 (94%) #SSc patients & 450/469 (96%) of SSc-ILD pts. GERD didnt influence ILD Dx or severity. But GERD Rx (PPI, H2RA) assoc w/ improved survival in those Scleroderma pts with ILD (p = 0.002) https://t.co/stQkpbmBCP https://t.co/e4BBz5c0av

Links:

Dr. John Cush RheumNow ( View Tweet)
Longitudinal US RA Registry of 31129 #RA pts (148K Pt-Yrs F/U) shows Higher RA Dz activity assoc w/ eGFR decline & renal dysfunction. Compared to remission, pts in Hi Dz activity had HR 1.27 risk for CKD G3a (<60cc) & HR 1.93 for CKD 3b (<45cc/min) https://t.co/UaFINRzqoM https://t.co/XXQviVO6jU

Links:

Dr. John Cush RheumNow ( View Tweet)
IgG4-related disease Nearly any organ can be affected ▶️Salivary glands ▶️Lacrimal glands ▶️Orbit ▶️Pancreatobiliary system ▶️Lung ▶️Kidney ▶️Retroperitoneum 👉🏽https://t.co/758F5iuYwT via @RheumJnl https://t.co/ipONrygHmc

Links:

Dr Ai Lyn Tan DrAiLynTan ( View Tweet)
Retrospective study from Univ of Tokyo on 194 Behcets dz (BD) pts, found 25% who developed intestinal BD (meanF/U 12 yrs). Use of #PPI significantly incr risk of intestinal BD (adj HR 2.48; vs non-PPI), w/ a confirmed duration/dose-dependent relationship. https://t.co/qFeS8svMLj https://t.co/KT8OBrY96S

Links:

Dr. John Cush RheumNow ( View Tweet)
Finding Spondylitis Among Psoriasis, Uveitis and Colitis Patients Maksymowych and colleagues have shown that screening patients with either psoriasis, iritis, or colitis may yield a surprising percentage meeting ASAS criterial for axSpA. https://t.co/lVCdGnMVaT https://t.co/jFILeHrQXj

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×